Flexion Therapeutics, Inc. (NASDAQ:FLXN) is reporting third quarter earnings results on Wednesday 4th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.51 per share.
For the full year, analysts predict revenues of $ 85.16 million, while looking forward to loss of $ 2.7 per share.
Previous Quarter Performance
Flexion Therapeutics, Inc. outlined loss for the second quarter of $ 0.76 per share, from the revenue of $ 15.45 million. According to street consensus, FLXN was expected to report 2Q20 loss of $ 0.65 per share from revenue of $ 16.34 million. The bottom line results missed street analysts by $ 0.11 or 16.92 percent, at the same time, top line results fell short of analysts by $ 0.89 million or 5.45 percent.
Stock Performance
Shares of Flexion Therapeutics, Inc. traded low $ -0.02 or -0.17 percent on Tuesday, reaching $ 12.00 with volume of 558.50 thousand shares. Flexion Therapeutics, Inc. has traded high as $ 12.38 and has cracked $ 11.92 on the downward trend
According to the previous trading day, closing price of $ 12.00, representing a 139.92 % increase from the 52 week low of $ 5.01 and a 47.69 % decrease over the 52 week high of $ 22.98.
The company has a market capital of $ 591.63 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee.
